<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5667816</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0187266</article-id><article-id pub-id-type="publisher-id">PONE-D-17-10191</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject><subj-group><subject>Physical Activity</subject><subj-group><subject>Physical Fitness</subject><subj-group><subject>Exercise</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Sports and Exercise Medicine</subject><subj-group><subject>Exercise</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Sports Science</subject><subj-group><subject>Sports and Exercise Medicine</subject><subj-group><subject>Exercise</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Glycobiology</subject><subj-group><subject>Glycosylamines</subject><subj-group><subject>Nucleosides</subject><subj-group><subject>Adenosine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiology</subject><subj-group><subject>Heart Rate</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Musculoskeletal System</subject><subj-group><subject>Muscles</subject><subj-group><subject>Skeletal Muscles</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Musculoskeletal System</subject><subj-group><subject>Muscles</subject><subj-group><subject>Skeletal Muscles</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Musculoskeletal System</subject><subj-group><subject>Muscles</subject><subj-group><subject>Cardiac Muscles</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Musculoskeletal System</subject><subj-group><subject>Muscles</subject><subj-group><subject>Cardiac Muscles</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Surgical and Invasive Medical Procedures</subject><subj-group><subject>Biopsy</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Sports and Exercise Medicine</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Sports Science</subject><subj-group><subject>Sports and Exercise Medicine</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Mutation</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Effects of AMPD1 common mutation on the metabolic-chronotropic relationship: Insights from patients with myoadenylate deaminase deficiency </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">Chronotropic response in myoadenylate deaminase deficiency</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6643-0527</contrib-id><name><surname>Rannou</surname><given-names>Fabrice</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing – original draft</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Scotet</surname><given-names>Virginie</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Software</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Marcorelles</surname><given-names>Pascale</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Validation</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Monnoyer</surname><given-names>Roxane</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Validation</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Le Maréchal</surname><given-names>Cédric</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Physiology Department-EA 4324, CHRU Cavale Blanche, Brest, France</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Institut National de la Santé et de la Recherche Médicale - UMR 1078, Brest, France</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Pathology Department-EA 4685 LNB, CHRU Morvan, Brest, France</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>MacGowan</surname><given-names>Guy A</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Freeman Hospital, UNITED KINGDOM</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><text><SENT sid="1" pm="."><plain>Competing Interests: The authors have declared that no competing interests exist. </plain></SENT>
</text></p></fn><corresp id="cor001">* E-mail: <email>fabrice.rannou@chu-brest.fr</email></corresp></author-notes><pub-date pub-type="epub"><day>2</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>11</issue><elocation-id>e0187266</elocation-id><history><date date-type="received"><day>15</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>17</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>© 2017 Rannou et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Rannou et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0187266.pdf"/><abstract><sec id="sec001"><title><text><SENT sid="2" pm="."><plain>Purpose </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="3" pm="."><plain>Current evidence indicates that the common AMPD1 gene variant is associated with improved survival in patients with advanced heart failure. </plain></SENT>
<SENT sid="4" pm="."><plain>Whilst adenosine has been recognized to mediate the cardioprotective effect of C34T AMPD1, the precise pathophysiologic mechanism involved remains undefined to date. </plain></SENT>
<SENT sid="5" pm="."><plain>To address this issue, we used cardio-pulmonary exercise testing data (CPX) from subjects with myoadenylate deaminase (MAD) defects. </plain></SENT>
</text></SecTag></p></sec><sec id="sec002"><title><text><SENT sid="6" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="7" pm="."><plain>From 2009 to 2013, all the patients referred in our laboratory to perform a metabolic exercise testing, i.e. a CPX with measurements of muscle metabolites in plasma during and after exercise testing, were prospectively enrolled. </plain></SENT>
<SENT sid="8" pm="."><plain>Subjects that also underwent an open muscle biopsy for diagnosis purpose were finally included. </plain></SENT>
<SENT sid="9" pm="."><plain>The metabolic-chronotropic response was assessed by calculating the slope of the linear relationship between the percent heart rate reserve and the percent metabolic reserve throughout exercise. </plain></SENT>
<SENT sid="10" pm="."><plain>MAD activity was measured using the Fishbein’s technique in muscle biopsy sample. </plain></SENT>
<SENT sid="11" pm="."><plain>The common AMPD1 mutation was genotyped and the AMPD1 gene was sequenced to screen rare variants from blood DNA. </plain></SENT>
</text></SecTag></p></sec><sec id="sec003"><title><text><SENT sid="12" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="13" pm="."><plain>Sixty-seven patients were included in the study; 5 had complete MAD deficiency, 11 had partial MAD deficiency, and 51 had normal MAD activity. </plain></SENT>
<SENT sid="14" pm="."><plain>Compared with normal MAD activity subjects, MAD deficient subjects appeared to have a lower-than-expected metabolic-chronotopic response during exercise. </plain></SENT>
<SENT sid="15" pm="."><plain>The metabolic-chronotropic relationship is more closely correlated with MAD activity in skeletal muscle (Rs = 0.57, p = 5.93E-7, Spearman correlation) than the presence of the common AMPD1 gene variant (Rs = 0.34, p = 0.005). </plain></SENT>
<SENT sid="16" pm="."><plain>Age-predicted O2 pulse ratio is significantly increased in MAD deficient subjects, indicating a greater efficiency of the cardiovascular system to deliver O2 (p &lt; 0.01, Scheffé’s post hoc test). </plain></SENT>
</text></SecTag></p></sec><sec id="sec004"><title><text><SENT sid="17" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="18" pm="."><plain>The metabolic-chronotropic response is decreased in skeletal muscle MAD deficiency, suggesting a biological mechanism by which AMPD1 gene exerts cardiac effect. </plain></SENT>
</text></SecTag></p></sec></abstract><funding-group><funding-statement>The authors received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="3"/><page-count count="13"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><SecTag type="INTRO"><sec sec-type="intro" id="sec005"><title><text><SENT sid="19" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="20" pm="."><plain>The clinical course and long-term outcome of patients with chronic heart failure (CHF) vary widely among individuals. </plain></SENT>
<SENT sid="21" pm="."><plain>In recent years, the genotype background has received increased attention owing to the existence of modifier genes that can modulate the severity and progression of heart diseases [1]. </plain></SENT>
<SENT sid="22" pm="."><plain>In 1999, using Kaplan-Meier survival-time plot analysis, Loh et al. first reported in end-stage cardiomyopathy a significantly greater probability of survival associated with carriage of the AMPD1 gene common mutation [2]. AMPD1 codes for the skeletal muscle isoform of myoadenylate deaminase (MAD). </plain></SENT>
<SENT sid="23" pm="."><plain>MAD promotes the deamination of adenosine monophosphate (AMP) to inosine monophosphate (IMP). </plain></SENT>
<SENT sid="24" pm="."><plain>A common mutation in the AMPD1 gene second exon (so-called C34T) in the homozygous state led to a truncated, catalytically inactive enzyme [3]. </plain></SENT>
<SENT sid="25" pm="."><plain>As a result, MAD deficiency is the most common enzymatic defect of skeletal muscle [3–7]. </plain></SENT>
<SENT sid="26" pm="."><plain>Despite intense study, the exact pathophysiological mechanism behind the beneficial effect of AMPD1 common mutation on cardiac function remains elusive. </plain></SENT>
<SENT sid="27" pm="."><plain>Nonetheless, there is ample evidence indicating that adenosine contributes significantly to the cardiovascular effects of C34T AMPD1 [8–10]. </plain></SENT>
</text></p><p><text><SENT sid="28" pm="."><plain>Due to MAD defect, AMP accumulates in muscle and the alternative pathway for AMP catabolism is to form adenosine by dephosphorylation via two different 5'-nucleotidases, the ecto-5'-nucleotidase and the AMP-selective cytosolic 5'-nucleotidase [11]. </plain></SENT>
<SENT sid="29" pm="."><plain>During exercise, the production of adenosine is therefore increased several fold in MAD deficient patient [8, 9], leading to subsequent positive effects on cardiovascular function. </plain></SENT>
<SENT sid="30" pm="."><plain>Adenosine has been shown to promote a beneficial vasodilatation for coronary blood supply [12], anti arythmic effect [10, 12, 13]. </plain></SENT>
<SENT sid="31" pm="."><plain>Further, it has also been shown that adenosine exerts negative chronotropic response via sinus atrial [12], even in the presence of catecholamines as during exercise [14]. </plain></SENT>
<SENT sid="32" pm="."><plain>An unresolved issue is that it is not clear whether the beneficial effect of adenosine on cardio-vascular function is linked to C34T or the muscle AMP activity. </plain></SENT>
<SENT sid="33" pm="."><plain>Patients with known MAD deficiency may provide a useful knock-out model of AMPD1 defect to study the effects of adenosine on cardio-vascular function during exercise [4]. </plain></SENT>
</text></p><p><text><SENT sid="34" pm="."><plain>During incremental exercise, the heart rate increase (i.e., chronotropic response) is strongly correlated with oxygen consumption increase. </plain></SENT>
<SENT sid="35" pm="."><plain>To calculate this linear relationship between the chronotropic and metabolic responses during dynamic incremental exercise (metabolic-chronotropic relationship, MCR), Wilkoff et al. have proposed a mathematical model [15]. </plain></SENT>
<SENT sid="36" pm="."><plain>The strength of this model is that it allows comparison between subjects irrespective of gender and anthropometric data, and is reliable even in case of submaximal exercise. </plain></SENT>
</text></p><p><text><SENT sid="37" pm="."><plain>Consequently, the purpose of this study was twofold. </plain></SENT>
<SENT sid="38" pm="."><plain>First, we hypothesized that the increase in adenosine production in MAD deficient patients modulates their chronotropic response during exercise. </plain></SENT>
<SENT sid="39" pm="."><plain>Second, we sought to examine the respective effects of AMPD1 common mutation and MAD deficiency on MCR by using cardio-pulmonary exercise testing (CPX) data from subjects with known MAD activity (i.e., Absent, Decreased, and Normal) in skeletal muscle. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="sec006"><title><text><SENT sid="40" pm="."><plain>Materials and methods </plain></SENT>
</text></title><sec id="sec007"><title><text><SENT sid="41" pm="."><plain>Design and subjects </plain></SENT>
</text></title><p><text><SENT sid="42" pm="."><plain>This was an observational study performed at the Physiology Department of Brest Hospital from May 2009 to December 2013 in patients with exercise-related myalgia. </plain></SENT>
<SENT sid="43" pm="."><plain>All the patients (age &gt; 16 years) referred in our laboratory to perform a metabolic exercise testing, i.e. a CPX with measurements of muscle metabolites in plasma during and after exercise testing (for more details, see [16]), were prospectively enrolled. </plain></SENT>
<SENT sid="44" pm="."><plain>In this cohort, subjects that also underwent an open muscle biopsy for diagnosis purpose were finally included. </plain></SENT>
<SENT sid="45" pm="."><plain>Exclusion criteria were as follows: (a) history of heart disease, neuropathy (b) use of ß-blocking agents, digitalis, calcium channel blockers, amiodarone, (c) arrhythmias preventing proper HR assessment. </plain></SENT>
<SENT sid="46" pm="."><plain>Furthermore, the presence of diabetes mellitus and thyroid dysfunction were ruled out by medical history, physical examination, and measurement of fasting glycemia and TSH. </plain></SENT>
</text></p><p><text><SENT sid="47" pm="."><plain>A group of eighteen healthy age-matched individuals, referred to undergo CPX to assess their physical fitness in our department, were recruited as controls for comparison of exercise responses. </plain></SENT>
<SENT sid="48" pm="."><plain>Controls were sedentary or moderately active subjects, with no history of muscle or cardiovascular diseases, and their physical examination was normal. </plain></SENT>
<SENT sid="49" pm="."><plain>Other exclusion criteria were similar to those used for the patients with exercise-induced myalgia. </plain></SENT>
</text></p><p><text><SENT sid="50" pm="."><plain>The study conforms to the principles outlined in the Declaration of Helsinki. </plain></SENT>
<SENT sid="51" pm="."><plain>The Institutional Ethics Committee at Brest University Medical Center approved the study. </plain></SENT>
<SENT sid="52" pm="."><plain>Each participant, and their legal representatives if they were minor, completed a written informed consent prior to participation (Clinical Trial NCT02362685). </plain></SENT>
</text></p></sec><sec id="sec008"><title><text><SENT sid="53" pm="."><plain>Exercise protocol </plain></SENT>
</text></title><p><text><SENT sid="54" pm="."><plain>All tests were performed in the morning after an overnight fast. </plain></SENT>
<SENT sid="55" pm="."><plain>Subjects were requested to refrain from exercise in the 48 hours before the study and from caffeine consumption on the day of the test. </plain></SENT>
<SENT sid="56" pm="."><plain>Each subjects performed a symptom-limited cardio-pulmonary exercise testing (CPX) on and electronically braked cycle ergometer (Ergoline GmbH, Bitz, Germany). </plain></SENT>
<SENT sid="57" pm="."><plain>Gas exchange was measured breath-by-breath using a MedGraphics CPX gas exchange system (Medical Graphics Corporation, St. Paul, Minnesota). </plain></SENT>
<SENT sid="58" pm="."><plain>The pneumotachometer and the O2 and CO2 analyzers were calibrated and the environmental temperature, percent humidity, and barometric pressure updated before each exercise session. </plain></SENT>
<SENT sid="59" pm="."><plain>The surface ECG was continuously monitored an blood pressure was measured every 2 min. </plain></SENT>
<SENT sid="60" pm="."><plain>Resting oxygen consumption and heart rate were calculated as the mean value during the last 2 minutes prior to starting exercise. </plain></SENT>
<SENT sid="61" pm="."><plain>In order to exhaust each subject’s limit of tolerance within 8–12 min, the predicted maximal power (PMP) was determined according to anthropometric data [17–18]. </plain></SENT>
<SENT sid="62" pm="."><plain>The test started with an initial 2-min workload of 20% PMP, with an increment of 10% PMP per minute. </plain></SENT>
<SENT sid="63" pm="."><plain>All patients were verbally encouraged to reach volitional exhaustion. </plain></SENT>
</text></p><p><text><SENT sid="64" pm="."><plain>The predicted peak VO2 values were determined according to the equations proposed by Wasserman and Hansen [19]. </plain></SENT>
<SENT sid="65" pm="."><plain>Percent-predicted maximal power was calculated according to normative values proposed by Jones [18]. </plain></SENT>
</text></p><p><text><SENT sid="66" pm="."><plain>The MCR, also referred to as chronotropic index, was calculated from the ratio of the heart rate reserve (HRR) to the metabolic reserve (i.e. V’O2 reserve) throughout incremental exercise [15]. </plain></SENT>
<SENT sid="67" pm="."><plain>The percent heart rate reserve (%HRR) at each stage of exercise was calculated as follows [15]: %HRR=HRstage−HRrestHRmax−HRrest Where HRstage is the heart rate at a given stage; HRrest is the heart rate at rest, calculated as the average of heart rate during the 2-min rest period before exercise; HRmax is the age predicted maximal heart rate given by 220-age (in years). </plain></SENT>
</text></p><p><text><SENT sid="68" pm="."><plain>The percent metabolic reserve (%V’O2 reserve) was calculated as follows [15]: %V′O2reserve=V′O2stage−V′O2restV′O2max−V′O2rest Where V’O2stage is the oxygen consumption at a particular stage; V’O2 rest and V’O2 max are the resting and the maximal oxygen consumptions, respectively. </plain></SENT>
</text></p><p><text><SENT sid="69" pm="."><plain>Data were plotted as %HRR versus %V’O2 reserve at each 30s exercise from rest to peak exercise. </plain></SENT>
<SENT sid="70" pm="."><plain>The slope of the linear relationship (reserve slope) was computed for each subject by linear regression analysis. </plain></SENT>
</text></p><p><text><SENT sid="71" pm="."><plain>Peak O2 pulse was expressed as a percentage of the predicted value achieved by dividing predicted peak V’O2 by the predicted maximal heart rate [20]. </plain></SENT>
<SENT sid="72" pm="."><plain>Forehead pulse oximetry (Nonin 8000R, Nonin Medical, Inc., Plymouth, MA) was used to monitor arterial O2 saturation [21]. </plain></SENT>
<SENT sid="73" pm="."><plain>Hemoglobin concentration was determined before exercise from venous blood sample. </plain></SENT>
</text></p></sec><sec id="sec009"><title><text><SENT sid="74" pm="."><plain>AMPD1 gene testing </plain></SENT>
</text></title><p><text><SENT sid="75" pm="."><plain>Genomic DNA was extracted from whole blood. </plain></SENT>
<SENT sid="76" pm="."><plain>The genotyping was restricted to the main single nucleotide mutation of the AMPD1 gene (rs17602729) previously named C34T in most previously published studies. </plain></SENT>
<SENT sid="77" pm="."><plain>The nucleotide numbering starts to the A of the first translated codon according to the Human genome variation society nomenclature based on the reference transcript NM_000036.1. </plain></SENT>
<SENT sid="78" pm="."><plain>Genotyping was performed by 5’-nuclease assay with MGB probes (TaqMan SNP genotyping assay thermo Fisher, ref. </plain></SENT>
<SENT sid="79" pm="."><plain>C__33603912_10) on a Lightcycler 480 (Roche) system. </plain></SENT>
<SENT sid="80" pm="."><plain>Sanger sequencing was performed to look for rare variants within the 16 exons and their flanking introns (reference sequence NM_000036.2). </plain></SENT>
<SENT sid="81" pm="."><plain>Bigdye terminator v1.1 cycle sequencing kit (ThermoFisher) was used and the sequences were aligned with SeqPilot software (JSI Medisys; sequencing primers available upon request). </plain></SENT>
</text></p></sec><sec id="sec010"><title><text><SENT sid="82" pm="."><plain>MyoAdenylate deaminase activity measurement </plain></SENT>
</text></title><p><text><SENT sid="83" pm="."><plain>Histo-enzymology was performed on fresh-frozen muscle biopsies from deltoid or vastus lateralis. </plain></SENT>
<SENT sid="84" pm="."><plain>MAD activity was demonstrated by the incubation (22 ± 2°C for 1 hour) of muscle transverse sections in Fishbein’s medium containing substrate (adenosine monophosphate, 1.2 M) and an electron acceptor (p-nitro-blue tetrazolium, 3.2 mM), potassium chloride (0.2 M), and dithiothreitol (0.1 M) at pH 6.1. </plain></SENT>
<SENT sid="85" pm="."><plain>After staining, the sections were rinsed with distilled water and mounted in glycerin jelly. </plain></SENT>
</text></p><p><text><SENT sid="86" pm="."><plain>The end-product of the Fishbein’s technique (i.e. p-NBT formazan) gives a blue staining with a wide absorption spectrum. </plain></SENT>
<SENT sid="87" pm="."><plain>MAD activity determinations were made using digitized stained sections as blue-level images (Olympus BX51 color camera, Hamburg, Germany). </plain></SENT>
<SENT sid="88" pm="."><plain>The optical density (OD) of MAD activity-staining was calculated for each section (Mesurim Pro Software, jean-francois.madre@ac-amiens.fr) according to the equation: OD=100*log10(IoIx) Where Io is the measured intensity of light transmitted through slide, cover-slip and mounting medium in areas immediately adjacent to the muscle section, and Ix is the intensity of light transmitted through muscle tissue. </plain></SENT>
<SENT sid="89" pm="."><plain>To provide an objective judgment of relative staining intensity, OD was compared to stains from the same series, namely biopsy samples from other patients processed at the same time [16]. </plain></SENT>
<SENT sid="90" pm="."><plain>For the purpose of comparing the MCR according to AMPD1 C34T genotype and MAD activity, the latter was divided in three subgroups (Normal, Decreased, Absent) as previously reported [6,16,22]. </plain></SENT>
</text></p></sec><sec id="sec011"><title><text><SENT sid="91" pm="."><plain>Statistics </plain></SENT>
</text></title><p><text><SENT sid="92" pm="."><plain>The data were first analyzed for normality and homogeneity of variances by using Shapiro-Wilk and Bartlett tests (95% confidence interval), respectively. </plain></SENT>
<SENT sid="93" pm="."><plain>Intergroup comparison was carried out using one-way ANOVA, followed by Scheffé’s post hoc analysis for multiple comparisons. </plain></SENT>
<SENT sid="94" pm="."><plain>The genotype-phenotype relationship between AMPD1 C34T and MAD activity can be formulated in a 3 x 3 contingency table. </plain></SENT>
<SENT sid="95" pm="."><plain>Agreement between AMPD1 C34T and MAD activity was evaluated using the weighted kappa statistics. </plain></SENT>
<SENT sid="96" pm="."><plain>Associations between MCR and AMPD1 C34T genotype, and between MCR and MAD activity, were measured using Spearman’ rank correlation coefficient (Rs). </plain></SENT>
<SENT sid="97" pm="."><plain>To assess whether any differences between these non independent Spearman’rank correlation magnitudes were statistically significant, we applied the Williams-Steiger’ t-test [23]. </plain></SENT>
<SENT sid="98" pm="."><plain>Data are reported as mean and standard deviation of the mean (SD). </plain></SENT>
<SENT sid="99" pm="."><plain>A p value of less than 0.05 (95% confidence level) was considered significant (SAS software, ver. 9.2). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="sec012"><title><text><SENT sid="101" pm="."><plain>Results </plain></SENT>
</text></title><p><text><SENT sid="102" pm="."><plain>We prospectively enrolled 74 patients, of which 7 subjects were excluded from statistical analysis because of an alternative diagnosis at muscle biopsy (glycogenosis and respiratory chain deficiency, n = 5 and 2, respectively). </plain></SENT>
<SENT sid="103" pm="."><plain>Complete MAD deaminase deficiency was found in 5 patients, partial MAD deaminase deficiency enzyme activity in 11 subjects, and normal MAD activity in 51 subjects. </plain></SENT>
</text></p><p><text><SENT sid="104" pm="."><plain>The distribution of base-line characteristics and CPX data in subjects is presented in Table 1. </plain></SENT>
<SENT sid="105" pm="."><plain>Partial or complete MAD deficiency has little impact on maximal O2 consumption (% predicted peak V’O2; p = 0.30, ANOVA). </plain></SENT>
<SENT sid="106" pm="."><plain>Conversely, the maximal heart rate at peak exercise was significantly decreased in the two MAD defect subgroups (% Predicted Maximal Heart Rate; p = 2.76 E-08, ANOVA). </plain></SENT>
<SENT sid="107" pm="."><plain>Although significant differences in RER at exhaustion were detected among groups by ANOVA, the inter-group post-hoc analysis did not reveal significant differences. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone.0187266.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0187266.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="108" pm="."><plain>Demographics data and exercise test responses according to skeletal muscle MAD activity and in controls subjects. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone.0187266.t001g" xlink:href="pone.0187266.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain>Absent </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>MAD activityDecreased </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain>Normal </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>Control </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>ANOVAF-value (p-value) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain>Number (n) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain>5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>11 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>51 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>17 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>Sex (f/m) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>2/3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>9/2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>9/42 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>9/8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>Age (years) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>32.6 ± 18.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>40.2 ± 13.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>35.8 ± 13.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain>36.5 ± 11.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>0.49 (0.69) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>BMI (kg.m-2) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>27.5 ± 10.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>22.6 ± 4.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>23.9 ± 4.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>25.4 ± 5.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>1.50 (0.22) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>Hemoglobin (g.dL-1) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>14.5 ± 1.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>13.8 ± 0.9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>14.6 ± 1.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>14.2 ± 1.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>1.88 (0.14) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>Resting Systolic BP (mmHg) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>124.2 ± 19.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>111.3 ± 15.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>114.4 ± 16.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>115.6 ± 14.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>0.79 (0.51) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>Resting Diastolic BP (mmHg) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>76.2 ± 17.9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>68.9 ± 12.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>73.7 ± 11.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>72.8 ± 12.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>0.61 (0.61) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>Peak exercise Systolic BP (mmHg) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>176.4 ± 19.9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>172.1 ± 29.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>170.0 ± 26.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>166.2 ± 20.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>0.25 (0.83) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>Peak exercise Diastolic BP (mmHg) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>83.6 ± 17.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>79.2 ± 17.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>83.0 ± 11.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>82.8 ± 14.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>0.26 (0.85) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>% Predicted maximal power </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>75.4 ± 23.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>90.9 ± 22.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>95.1 ± 21.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>98.8 ± 18.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>1.72 (0.17) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>Peak V’O2 (ml.min-1.kg-1) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>30.9 ± 16.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>30.9 ± 11.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>36.5 ± 10.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>32.1 ± 6.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>1.61 (0.19) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>% Predicted peak V’O2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>87.8 ± 23.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>100.6 ± 17.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>98.4 ± 15.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>103.3 ± 14.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>1.25 (0.30) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>Heart Rate at end-exercise (beats/min-1) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>137.6 ± 22.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>150.3 ± 23.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>172.3 ± 16.8 *† </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>175.4 ± 11.0 *† </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>11.21 (3.22E-06) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>% Predicted Maximal Heart Rate </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>73.2 ± 6.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>83.4 ± 10.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>93.6 ± 7.6 *† </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>95.6 ± 6.2 *† </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>16.12 (2.76E-08) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>RER at peak exercise </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="197" pm="."><plain>1.10 ± 0.12 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="198" pm="."><plain>1.17 ± 0.09 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="199" pm="."><plain>1.21 ± 0.08 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>1.22 ± 0.07 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="201" pm="."><plain>3.17 (0.03) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="202" pm="."><plain>Pulse oximetry at peak exercise (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="203" pm="."><plain>97.8 ± 2.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="204" pm="."><plain>98.6 ± 1.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>97.6 ± 1.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="206" pm="."><plain>97.9 ± 1.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>1.56 (0.21) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>Metabolic-Chronotropic Relationship </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="209" pm="."><plain>0.54 ± 0.12 ‡ </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="210" pm="."><plain>0.75 ± 0.13 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>0.91 ± 0.13*† </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>0.93 ± 0.12*† </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>18.04 (4.9E-09) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>% Predicted maximal O2 pulse </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>119.0 ± 26.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>120.1 ± 9.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>105.1 ± 16.2 ‡ </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>107.9 ± 13.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>3.60 (0.02) </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p><text><SENT sid="220" pm="."><plain>MyoAdenylate Deaminase, f female, m male, BMI Body Mass Index, BP Blood Pressure, RER Respiratory Exchange Ratio. </plain></SENT>
<SENT sid="221" pm="."><plain>Data are means ± SD. </plain></SENT>
<SENT sid="222" pm="."><plain>Comparisons between groups were made using analysis of variance and Scheffe’s post-hoc test. </plain></SENT>
<SENT sid="223" pm="."><plain>Data are presented as mean ± SD. </plain></SENT>
</text></p></fn><fn id="t001fn002"><p><text><SENT sid="224" pm="."><plain>* p &lt; 0.001 versus MAD Absent. </plain></SENT>
</text></p></fn><fn id="t001fn003"><p><text><SENT sid="225" pm="."><plain>† p &lt; 0.01 versus MAD Decreased. </plain></SENT>
</text></p></fn><fn id="t001fn004"><p><text><SENT sid="226" pm="."><plain>‡ p &lt; 0.05 versus MAD Decreased. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="227" pm="."><plain>Table 2 presents the genotype-phenotype relationship between AMPD1 c34T and MAD activity. </plain></SENT>
<SENT sid="228" pm="."><plain>Four patients carried the AMPD1 C34T mutation in homozygosity, and 12 patients were heterozygotes. </plain></SENT>
<SENT sid="229" pm="."><plain>The weighted kappa coefficient between AMPD1 C34T and MAD activity was 0.76 with 95% CI (0.60, 0.93). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone.0187266.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0187266.t002</object-id><label>Table 2</label><caption><title><text><SENT sid="230" pm="."><plain>Confusion matrix of MAD activity in skeletal muscle vs. the most common AMPD1 mutation in patients. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone.0187266.t002g" xlink:href="pone.0187266.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>Normal MAD activity </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>Decreased MAD activity </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>Absent MAD activity </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>C34T Wild-Type </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>46 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>C34T heterozygous </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>1 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>C34T homozygous </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>4 </plain></SENT>
</text></td></tr></tbody></table></alternatives></table-wrap></SecTag><p><text><SENT sid="243" pm="."><plain>Sequence analysis of the entire coding region of AMPD1 revealed less frequent mutations in the present cohort (Table 3). </plain></SENT>
<SENT sid="244" pm="."><plain>Analysis of exon 7 revealed the presence of the A860T mutation in four subjects (patients 1–4). </plain></SENT>
<SENT sid="245" pm="."><plain>One subject was A860T homozygous (patient 2), two subjects were simple heterozygote (patients 1 and 3), and one subject was C34T/A860T compound heterozygote (patient 4). </plain></SENT>
<SENT sid="246" pm="."><plain>A 56-yr-old subject with absent MAD activity in skeletal muscle (patient 5) was found to be compound heterozygous for the C34T and G468T mutations. </plain></SENT>
<SENT sid="247" pm="."><plain>Unfortunately, parental DNA was not available to determine allele segregation and location of the two mutations. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone.0187266.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0187266.t003</object-id><label>Table 3</label><caption><title><text><SENT sid="248" pm="."><plain>AMPD1 rare variants carriers phenotype for the metabolic-chronotropic relationship and the predicted maximal O2 pulse. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone.0187266.t003g" xlink:href="pone.0187266.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>Patient No. </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>MAD activity </plain></SENT>
</text></th><th align="center" colspan="2" rowspan="1"><text><SENT sid="251" pm="."><plain>AMPD1 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>Metabolic-Chronotropic Relationship </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>% Predicted maximal O2 pulse </plain></SENT>
</text></th></tr><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>C34T Genotype </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>Rare variants(ref seq NM_000036.1) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>Normal </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>Wild-TypeC/C </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>c.860A&gt;T-p.K287IHeterozygote </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>0.927 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>95.8 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>Normal </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>Wild-TypeC/C </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>c.860A&gt;T-p.K287IHomozygote </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>0.796 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>112.0 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>Decreased </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>Wild-TypeC/C </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>c.860A&gt;T-p.K287IHeterozygote </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>0.730 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>126.4 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>Decreased </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>HeterozygoteC/T </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>c.860A&gt;T-p.K287IHeterozygote </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>0.744 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>114.7 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain>5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>Absent </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>HeterozygoteC/T </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>c.468G&gt;T-p.Q156HHeterozygote </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>0.511 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>155.2 </plain></SENT>
</text></td></tr></tbody></table></alternatives></table-wrap></SecTag><p><text><SENT sid="286" pm="."><plain>Fig 1 displays the effects of AMPD1 C34T and MAD activity on the MCR. </plain></SENT>
<SENT sid="287" pm="."><plain>As previously, we first sought to characterize our phenotype according to the previously and widely used methodology (i.e., AMPD1 C34T genotype, Fig 1B left panel). </plain></SENT>
<SENT sid="288" pm="."><plain>The spearman correlation coefficient (Rs) between the MCR and the AMPD1 C34T genotype was 0.34 (p = 0.005), and between the MCR and MAD activity was 0.57 (p = 5.93E-7). </plain></SENT>
<SENT sid="289" pm="."><plain>Williams' t-test revealed a significant statistical difference between these two dependent correlation (p = 0.015). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0187266.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0187266.g001</object-id><label>Fig 1</label><caption><title><text><SENT sid="290" pm="."><plain>Effects of AMPD1 C34T and MAD activity on the metabolic-chronotropic relationship. </plain></SENT>
</text></title><p><text><SENT sid="291" pm="."><plain>A Representative plots of the heart rate versus oxygen consumption according to MAD activity in three patients and in one control subject. </plain></SENT>
<SENT sid="292" pm="."><plain>For comparison, the four subjects have similar anthropometric data, i.e. similar predicted values for maximal exercise testing data. f, female. </plain></SENT>
<SENT sid="293" pm="."><plain>MCR, metabolic-chronotropic relationship. </plain></SENT>
<SENT sid="294" pm="."><plain>B Scatter plots reporting the metabolic-chronotropic relationship according to the AMPD1 C34T genotype (left panel) and the MAD activity (right panel). </plain></SENT>
<SENT sid="295" pm="."><plain>Horizontal bars represent the mean. </plain></SENT>
<SENT sid="296" pm="."><plain>Rs, Spearman’s rank correlation coefficient along with associated two-tailed p value. *Significantly different from the C34T-genotype spearman correlation coefficient (Williams-Steiger’ t-test, p = 0.015). </plain></SENT>
<SENT sid="297" pm="."><plain>Intergroup comparison was performed by one way ANOVA followed by the Scheffe post hoc test. † significantly different from MAD Absent (p &lt; 0.05). ‡ significantly different from MAD Absent (p &lt; 0.001). § significantly different from MAD Decreased (p &lt; 0.01). </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0187266.g001"/></fig></SecTag><p><text><SENT sid="298" pm="."><plain>Such difference in the metabolic-chonotropic response according to MAD activity prompted us to analyse the predicted oxygen pulse ratio (Fig 2). </plain></SENT>
<SENT sid="299" pm="."><plain>ANOVA revealed significant differences among the groups (F = 3.60, p = 0.017). </plain></SENT>
<SENT sid="300" pm="."><plain>The post hoc contrasts according to the Scheffé method rejected the null hypothesis positing (mean MAD Absent + mean MAD Decreased) − (mean MAD Normal + mean Control) = 0 (p &lt; 0.01), indicating that % age-predicted O2 pulse ratio is significantly increased in MAD defect (Absent and Decreased MAD activity). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0187266.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0187266.g002</object-id><label>Fig 2</label><caption><title><text><SENT sid="301" pm="."><plain>Effects of MAD activity on the % age-predicted O2 pulse. </plain></SENT>
</text></title><p><text><SENT sid="302" pm="."><plain>Horizontal bars represent the mean.* MAD defect (Absent MAD activity + Decreased MAD activity) significantly different from normal (Normal MAD activity + Control) according to the Scheffé grouping post hoc test (p &lt; 0.01). </plain></SENT>
<SENT sid="303" pm="."><plain>Inset, O2 pulse is determined by stroke volume (SV), hemoglobin content (Hb) and arteriovenous oxygen saturation difference. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0187266.g002"/></fig></SecTag></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="conclusions" id="sec013"><title><text><SENT sid="304" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="305" pm="."><plain>The seminal paper by Loh and colleagues [2] attracted tens of subsequent studies to identify the mechanisms underlying the beneficial effects of AMPD1 common variant on cardiovascular function. </plain></SENT>
<SENT sid="306" pm="."><plain>To address this issue, a significant amount of work has been devoted to studying the effects of C34T on clinical outcome of patients with CHF. </plain></SENT>
<SENT sid="307" pm="."><plain>In order to elucidate further this missing link in the genotype-phenotype relationship, we used CPX data from subjects whose MAD activity in skeletal muscle and C34T AMPD1 status were evaluated concurrently. </plain></SENT>
<SENT sid="308" pm="."><plain>Furthermore, it should be emphasized that cardiac patients are given rhythm modulator drugs, thereby altering their chronotropic response during exercise. </plain></SENT>
<SENT sid="309" pm="."><plain>Hence, the interest to study subjects free from cardiovascular disease and with known MAD activity in skeletal muscle. </plain></SENT>
</text></p><p><text><SENT sid="310" pm="."><plain>In the present study, we found 1) MAD deficient subjects have a lower metabolic-chronotropic response during exercise, and 2) this decrease response is more correlated to MAD activity in skeletal muscle compared to the C34T AMPD1 genotype. </plain></SENT>
</text></p><p><text><SENT sid="311" pm="."><plain>The beneficial effect of C34T on cardiovascular function was not observed in all studies [2,24–26]. </plain></SENT>
<SENT sid="312" pm="."><plain>Bearing in mind the non-linearity of the genotype-phenotype relation for AMPD1 C34T and MAD activity, we hypothesize that the equivocal findings reported in the literature may relate to the methodology in previous studies. </plain></SENT>
<SENT sid="313" pm="."><plain>The segregation of patients into two classes (AMPD1 C34T carriers vs. non carriers), rather than in three classes, may result in loss of statistical information. </plain></SENT>
<SENT sid="314" pm="."><plain>Less common AMPD1 G468T and A860T mutations can also alter MAD activity. </plain></SENT>
<SENT sid="315" pm="."><plain>The A860T mutation produces an amino acid substitution of lysine for leucine at residue 2871 of MAD enzyme, resulting in an approximately 50% loss of catalytic activity [27]. </plain></SENT>
<SENT sid="316" pm="."><plain>The G468T mutation results in a substitution of glutamine for histidine [28]. </plain></SENT>
<SENT sid="317" pm="."><plain>In this study, the patient harboring the combined mutation G468T/C34T in the heterozygous state exhibited an absence of MAD activity in muscle biopsy, in agreement with previous reports [28, 29]. </plain></SENT>
</text></p><p><text><SENT sid="318" pm="."><plain>As originally described by Wilkoff et al. [15], we used the 220-age equation to predict maximal heart rate and calculate the MCR. </plain></SENT>
<SENT sid="319" pm="."><plain>There is an ongoing debate about the use of Tanaka equation (208–0.7*age) rather than 220-age formula to predict maximal heart rate [30, 31]. </plain></SENT>
<SENT sid="320" pm="."><plain>In our data set, the two equations yield strikingly similar results, with a difference less than 0.5% in the different groups (data not shown). </plain></SENT>
<SENT sid="321" pm="."><plain>The consistency of the results probably lies in the age of our studied population, since the two equations produce the same results between 30 and 40 years old (see Fig 3 in [30]). </plain></SENT>
<SENT sid="322" pm="."><plain>It has long been recognized that during increasing exercise workloads, heart rate is linearly related to the rate of oxygen consumption. </plain></SENT>
<SENT sid="323" pm="."><plain>This strong physiological property was used by Wilkoff and Miller to develop their mathematical model [15]. </plain></SENT>
<SENT sid="324" pm="."><plain>Wilkoff and co-workers originally designed their model of the MCR in order to, first, objectively measure a chronotropic incompetence in heart disease patients and, second, to assess the beneficial effect of pace-maker implantation on heart-rate response during exercise. </plain></SENT>
<SENT sid="325" pm="."><plain>According to the Wilkoff’s model, the MCR slope of the normal sinus is 1.0 with a 95% confidence interval between 0.8 and 1.3 [15]. </plain></SENT>
<SENT sid="326" pm="."><plain>In heart failure patients, an MCR slope of &lt; 0.8 is considered indicative of chronotropic incompetence. </plain></SENT>
<SENT sid="327" pm="."><plain>Since subjects were free from cardiovascular disorders in this study, the lower metabolic chronotropic response in MAD deficient subjects should not be interpreted as chronotropic incompetence. </plain></SENT>
<SENT sid="328" pm="."><plain>Thus, our findings raise substantial and attractive issues from a physiological–“Fickian”- perspective. </plain></SENT>
</text></p><p><text><SENT sid="329" pm="."><plain>While MCR provides an assessment of the relationship between oxygen consumption and heart rate during exercise, the ratio of the maximal values of these two variables (O2 pulse) also provides valuable insights. </plain></SENT>
<SENT sid="330" pm="."><plain>According to the Fick equation, O2 pulse is numerically equal to the product of stroke volume (SV) and arteriovenous O2 content difference (CaO2- CvO2). </plain></SENT>
<SENT sid="331" pm="."><plain>During incremental exercise, the increase in oxygen pulse is due to both an increase in stroke volume and a widening of the arterial-venous oxygen concentration difference (Fig 2 inset). </plain></SENT>
<SENT sid="332" pm="."><plain>Since the hemoglobin content was similar among the groups and no desaturation was observed in the study population using pulse oximetry, the arterial content in O2 does not account for the higher O2 pulse values in MAD deficient patients. </plain></SENT>
<SENT sid="333" pm="."><plain>The higher O2 pulse values in MAD deficient subjects are therefore due to either or both a greater stroke volume or a greater oxygen extraction. </plain></SENT>
<SENT sid="334" pm="."><plain>Given that during maximum exercise the latter vary within a very limited range [19], the higher O2 pulse values of the MAD deficient subjects must correspond to a greater stroke volume. </plain></SENT>
<SENT sid="335" pm="."><plain>In agreement with this view, it has recently been shown that CHF patients with CT + TT genotype of AMPD1 C34T polymorphism have an elevated left ventricular ejection fraction compared with CC genotype [32]. </plain></SENT>
<SENT sid="336" pm="."><plain>Finally, while further studies are required to establish the respective parts of increased stroke volume and arterio-venous difference, our results support the view of a greater efficiency of the cardiovascular system to deliver O2 in MAD deficient subjects. </plain></SENT>
<SENT sid="337" pm="."><plain>The lower lactate and RER values in MAD subjects [6,16,33] suggest a greater reliance on oxidative energy production. </plain></SENT>
<SENT sid="338" pm="."><plain>Our results are in agreement with previous studies showing an improvement of performance in endurance events in athletes harbouring the AMPD1 common mutation [34]. </plain></SENT>
<SENT sid="339" pm="."><plain>Since only a few part of AMPD1 C34T carriers exhibit muscular complaints, the clinical relevance of this myopathy has been questioned [35]. </plain></SENT>
<SENT sid="340" pm="."><plain>As a reconciling alternative, one can hypothesized that the positive effect of AMPD1 C34T on cardiovascular function counterbalances the detrimental effects on skeletal muscle. </plain></SENT>
<SENT sid="341" pm="."><plain>From an evolutionary perspective, the beneficial effect of AMPD1 common mutation on cardiovascular function may therefore explain the high allele frequency in the general population. </plain></SENT>
</text></p><p><text><SENT sid="342" pm="."><plain>Several limitations need to be considered. </plain></SENT>
<SENT sid="343" pm="."><plain>First, given the nature of the studied population, the generalizability of the present findings to CHF patients is a crucial issue. </plain></SENT>
<SENT sid="344" pm="."><plain>Additional studies in subjects with CHF, using both muscle biopsies and data from CPX performed without HR modulators, are required. </plain></SENT>
<SENT sid="345" pm="."><plain>Furthermore, the observed correlation between MAD activity and MCR is based on three categories of MAD activity using histoenzymology. </plain></SENT>
<SENT sid="346" pm="."><plain>One might argue that the quantitative measurement of MAD activity using biochemical assay may provide a better correlation with MCR. </plain></SENT>
<SENT sid="347" pm="."><plain>Our segmentation of abnormal MAD activity into two subgroups according to p-NBT staining is in agreement with the methodology of Tarnopolsky et al. [6] using an absent MAD activity group with no MAD staining and a decreased MAD activity group with low staining to study the pathophysiology of MADD. </plain></SENT>
<SENT sid="348" pm="."><plain>It has been shown that low MAD staining in cryosections is correlated to reduced in vitro MAD activity in biochemical assays [6,36,37]. </plain></SENT>
<SENT sid="349" pm="."><plain>The potential for bias was also reduced through the comparison of each patient to biopsy specimens from different patients analyzed at the same time. </plain></SENT>
<SENT sid="350" pm="."><plain>Further, the Spearman coefficient we used to calculate the level of correlation between MAD activity and MCR is robust, as a non-parametric method. </plain></SENT>
<SENT sid="351" pm="."><plain>Factors other than MAD activity may also influence the chronotropic response during exercise, such as medications and medical conditions. </plain></SENT>
<SENT sid="352" pm="."><plain>However, common causes of CI have been ruled out in the study design and recruitment, and the similar age in the different groups minimizes the impact of the age-related decrease in maximal heart rate. </plain></SENT>
<SENT sid="353" pm="."><plain>We also acknowledge that the plasma levels of adenosine were not measured in this study, although the MCR was used as a functional marker of adenosine effects on heart. </plain></SENT>
<SENT sid="354" pm="."><plain>We wish to emphasize that adenosine determination in blood samples is challenging, owing to a very short half-life in plasma due to rapid transformation by deamination to inosine by adenosine deaminase, or by phosphorylation to AMP by adenosine kinase [38]. </plain></SENT>
<SENT sid="355" pm="."><plain>Additionally, in this “adenosine concept”, it is not completely clear whether adenosine is produced by skeletal muscle itself or cardiac muscle in MAD deficiency. </plain></SENT>
<SENT sid="356" pm="."><plain>Since the earlier study by Sabina et al. showing an increased adenosine production by skeletal muscle in MAD deficient subjects [8], the increase in blood adenosine levels was subsequently attributed to skeletal muscle [2]. </plain></SENT>
<SENT sid="357" pm="."><plain>A breakthrough in these studies came from Kalski et al. [9], who showed that, using cardiac muscle biopsy in CHF patients, MAD activity is decreased in C34T AMPD1 carriers. </plain></SENT>
<SENT sid="358" pm="."><plain>This suggests an in situ production of adenosine in heart in C34T AMPD1 carriers with ensuing paracrine protective effects on coronary circulation and chronotropic response. </plain></SENT>
<SENT sid="359" pm="."><plain>Finally, it should also be pointed out that the desensitization of adenosine receptors is less prone to occur in MAD deficient subject [39], since adenosine production is increased only during exercise [8, 9]. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec sec-type="conclusions" id="sec014"><title><text><SENT sid="360" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="361" pm="."><plain>Our study shows that the metabolic-chronotropic response is decreased in reduced skeletal muscle MAD activity. </plain></SENT>
<SENT sid="362" pm="."><plain>This finding reveals a biological mechanism that links AMPD1 gene to cardiac function. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="sec015"><title><text><SENT sid="363" pm="."><plain>Supporting information </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="pone.0187266.s001"><label>S1 File</label><caption><title><text><SENT sid="364" pm="."><plain>Dataset. </plain></SENT>
</text></title><p><text><SENT sid="365" pm="."><plain>(XLSX) </plain></SENT>
</text></p></caption><media xlink:href="pone.0187266.s001.xlsx"><caption><p><text><SENT sid="366" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0187266.s002"><label>S1 Fig</label><caption><title><text><SENT sid="367" pm="."><plain>Fig 2 inset. </plain></SENT>
</text></title><p><text><SENT sid="368" pm="."><plain>O2 pulse is determined by stroke volume (SV), hemoglobin content (Hb) and arteriovenous oxygen saturation difference. </plain></SENT>
</text></p><p><text><SENT sid="369" pm="."><plain>(DOC) </plain></SENT>
</text></p></caption><media xlink:href="pone.0187266.s002.doc"><caption><p><text><SENT sid="370" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="371" pm="."><plain>The authors are very grateful to Mrs. </plain></SENT>
<SENT sid="372" pm="."><plain>Marie-Claude Beaujon for technical assistance during exercise testing and to Mrs. </plain></SENT>
<SENT sid="373" pm="."><plain>Régine Le Bec for histochemical stainings of muscle biopsy. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="ABBR"><glossary><title>Abbreviations</title><def-list><def-item><term>CPX</term><def><p>Cardiopulmonary Exercise Testing</p></def></def-item><def-item><term>MAD</term><def><p>Myoadenylate Deaminase</p></def></def-item><def-item><term>MCR</term><def><p>Metabolic-Chronotropic Relationship</p></def></def-item></def-list></glossary></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="pone.0187266.ref001"><text><SENT sid="374" pm="."><plain>1RichardP, VillardE, CharronP, IsnardR. The genetic basis of cardiomyopathies. J Am Coll Cardiol. 2006;48(9 Suppl A):A79–89. </plain></SENT>
</text></ref><ref id="pone.0187266.ref002"><text><SENT sid="375" pm="."><plain>2LohE, RebbeckTR, MahoneyPD, DeNofrioD, SwainJL, HolmesEW. Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation. 1999;99(11):1422–5. </plain></SENT>
<SENT sid="376" pm="."><plain>Epub 1999/03/23. .<?supplied-pmid 10086964?>10086964 </plain></SENT>
</text></ref><ref id="pone.0187266.ref003"><text><SENT sid="377" pm="."><plain>3MorisakiT, GrossM, MorisakiH, PongratzD, ZollnerN, HolmesEW. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci U S A. 1992;89(14):6457–61. </plain></SENT>
<SENT sid="378" pm="."><plain>Epub 1992/07/15. <?supplied-pmid 1631143?>1631143 </plain></SENT>
</text></ref><ref id="pone.0187266.ref004"><text><SENT sid="379" pm="."><plain>4TarnopolskyMA. What can metabolic myopathies teach us about exercise physiology? Appl Physiol Nutr Metab. 2006;31(1):21–30. </plain></SENT>
<SENT sid="380" pm="."><plain>Epub 2006/04/11. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1139/h05-008">10.1139/h05-008</ext-link> .<?supplied-pmid 16604138?>16604138 </plain></SENT>
</text></ref><ref id="pone.0187266.ref005"><text><SENT sid="381" pm="."><plain>5FishbeinWN, ArmbrustmacherVW, GriffinJL. Myoadenylate deaminase deficiency: a new disease of muscle. Science. 1978;200(4341):545–8. </plain></SENT>
<SENT sid="382" pm="."><plain>Epub 1978/05/05. .<?supplied-pmid 644316?>644316 </plain></SENT>
</text></ref><ref id="pone.0187266.ref006"><text><SENT sid="383" pm="."><plain>6TarnopolskyMA, PariseG, GibalaMJ, GrahamTE, RushJW. Myoadenylate deaminase deficiency does not affect muscle anaplerosis during exhaustive exercise in humans. J Physiol. 2001;533(Pt 3):881–9. </plain></SENT>
<SENT sid="384" pm="."><plain>Epub 2001/06/19. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1469-7793.2001.t01-1-00881.x">10.1111/j.1469-7793.2001.t01-1-00881.x</ext-link> <?supplied-pmid 11410643?>11410643 </plain></SENT>
</text></ref><ref id="pone.0187266.ref007"><text><SENT sid="385" pm="."><plain>7FishbeinWN. Myoadenylate deaminase deficiency: inherited and acquired forms. Biochem Med. 1985;33(2):158–69. </plain></SENT>
<SENT sid="386" pm="."><plain>Epub 1985/04/01. .<?supplied-pmid 4004819?>4004819 </plain></SENT>
</text></ref><ref id="pone.0187266.ref008"><text><SENT sid="387" pm="."><plain>8SabinaRL, SwainJL, OlanowCW, BradleyWG, FishbeinWN, DiMauroS, et al Myoadenylate deaminase deficiency. </plain></SENT>
<SENT sid="388" pm="."><plain>Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle. J Clin Invest. 1984;73(3):720–30. </plain></SENT>
<SENT sid="389" pm="."><plain>Epub 1984/03/01. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1172/JCI111265">10.1172/JCI111265</ext-link> <?supplied-pmid 6707201?>6707201 </plain></SENT>
</text></ref><ref id="pone.0187266.ref009"><text><SENT sid="390" pm="."><plain>9KalsiKK, YuenAH, RybakowskaIM, JohnsonPH, SlominskaE, BirksEJ, et al Decreased cardiac activity of AMP deaminase in subjects with the AMPD1 mutation—a potential mechanism of protection in heart failure. Cardiovasc Res. 2003;59(3):678–84. </plain></SENT>
<SENT sid="391" pm="."><plain>Epub 2003/09/23. .<?supplied-pmid 14499869?>14499869 </plain></SENT>
</text></ref><ref id="pone.0187266.ref010"><text><SENT sid="392" pm="."><plain>10SommerschildHT, KirkeboenKA. Adenosine and cardioprotection during ischaemia and reperfusion—an overview. Acta Anaesthesiol Scand 2000;44:1038–55. <?supplied-pmid 11028722?>11028722 </plain></SENT>
</text></ref><ref id="pone.0187266.ref011"><text><SENT sid="393" pm="."><plain>11DarvishA, PomerantzR, ZografidesP, MettingP. Contribution of cytosolic and membrane-bound 5'-nucleotidases to cardiac adenosine production. Am J Physiol. 1996;27(5):2162–7. </plain></SENT>
</text></ref><ref id="pone.0187266.ref012"><text><SENT sid="394" pm="."><plain>12DruryAN, Szent-GyorgyiA. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol. 1929;68(3):213–37. </plain></SENT>
<SENT sid="395" pm="."><plain>Epub 1929/11/25. <?supplied-pmid 16994064?>16994064 </plain></SENT>
</text></ref><ref id="pone.0187266.ref013"><text><SENT sid="396" pm="."><plain>13DiMarcoJP, SellersTD, BerneRM, WestGA, BelardinelliL. Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia. Circulation. 1983;68(6):1254–63. </plain></SENT>
<SENT sid="397" pm="."><plain>Epub 1983/12/01. .<?supplied-pmid 6640877?>6640877 </plain></SENT>
</text></ref><ref id="pone.0187266.ref014"><text><SENT sid="398" pm="."><plain>14KirchhofP, FabritzL, FortmullerL, MatherneGP, LankfordA, BabaHA, et al Altered sinus nodal and atrioventricular nodal function in freely moving mice overexpressing the A1 adenosine receptor. Am J Physiol Heart Circ Physiol. 2003;285(1):H145–53. </plain></SENT>
<SENT sid="399" pm="."><plain>Epub 2003/03/15. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1152/ajpheart.01036.2002">10.1152/ajpheart.01036.2002</ext-link> .<?supplied-pmid 12637351?>12637351 </plain></SENT>
</text></ref><ref id="pone.0187266.ref015"><text><SENT sid="400" pm="."><plain>15WilkoffBL, MillerRE. Exercise testing for chronotropic assessment. Cardiol Clin. 1992;10(4):705–17. </plain></SENT>
<SENT sid="401" pm="."><plain>Epub 1992/11/01. .<?supplied-pmid 1423382?>1423382 </plain></SENT>
</text></ref><ref id="pone.0187266.ref016"><text><SENT sid="402" pm="."><plain>16RannouF, UguenA, ScotetV, Le MaréchalC, RigalO, MarcorellesP, et al Diagnostic algorithm for glycogenoses and myoadenylate deaminase deficiency based on exercise testing parameters: a prospective study. PLoS One. 2015;10(7):e0132972 doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0132972">10.1371/journal.pone.0132972</ext-link> <?supplied-pmid 26207760?>26207760 </plain></SENT>
</text></ref><ref id="pone.0187266.ref017"><text><SENT sid="403" pm="."><plain>17BaderDS, McInnisKJ, MaguireTE, PierceGL, BaladyGJ. Accuracy of a pretest questionnaire in exercise test protocol selection. Am J Cardiol. 2000;85(6):767–70, A8–9. </plain></SENT>
<SENT sid="404" pm="."><plain>Epub 2002/05/10. .<?supplied-pmid 12000058?>12000058 </plain></SENT>
</text></ref><ref id="pone.0187266.ref018"><text><SENT sid="405" pm="."><plain>18JonesNL, MakridesL, HitchcockC, ChypcharT, McCartneyN. Normal standards for an incremental progressive cycle ergometer test. Am Rev Respir Dis. 1985;131(5):700–8. </plain></SENT>
<SENT sid="406" pm="."><plain>Epub 1985/05/01. .<?supplied-pmid 3923878?>3923878 </plain></SENT>
</text></ref><ref id="pone.0187266.ref019"><text><SENT sid="407" pm="."><plain>19WassermanK, HansenJ, SueD, StringerW, WhippB. Normal values In: WeinbergR, ed. Principles of Exercise Testing and Interpretation. 4th ed Philadelphia, PA Lippincot Williams and Wilkins 2005:160–82. </plain></SENT>
</text></ref><ref id="pone.0187266.ref020"><text><SENT sid="408" pm="."><plain>20OliveiraR, MyersJ, AraùjoC. Long-term stability of the oxygen pulse curve during maximal exercise. Clinics. 2011;66(2):203–9. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/S1807-59322011000200004">10.1590/S1807-59322011000200004</ext-link> <?supplied-pmid 21484034?>21484034 </plain></SENT>
</text></ref><ref id="pone.0187266.ref021"><text><SENT sid="409" pm="."><plain>21YamayaY, BogaardHJ, WagnerPD, NiizekiK, HopkinsSR. Validity of pulse oximetry during maximal exercise in normoxia, hypoxia, and hyperoxia. J Appl Physiol. 2002;92:162–8. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1152/japplphysiol.00409.2001">10.1152/japplphysiol.00409.2001</ext-link> <?supplied-pmid 11744656?>11744656 </plain></SENT>
</text></ref><ref id="pone.0187266.ref022"><text><SENT sid="410" pm="."><plain>22ShumateJB, KatnikR, RuizM, KaiserK, FriedenC, BrookeMH, et al Myoadenylate deaminase deficiency. Muscle Nerve. 1979;2(3):213–6. </plain></SENT>
<SENT sid="411" pm="."><plain>Epub 1979/05/01. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/mus.880020309">10.1002/mus.880020309</ext-link> .<?supplied-pmid 503106?>503106 </plain></SENT>
</text></ref><ref id="pone.0187266.ref023"><text><SENT sid="412" pm="."><plain>23SteigerJ. Tests for comparing elements of a correlation matrix. Psychological Bull. 1980;87:245–51. </plain></SENT>
</text></ref><ref id="pone.0187266.ref024"><text><SENT sid="413" pm="."><plain>24AndersonJL, HabashiJ, CarlquistJF, MuhlesteinJB, HorneBD, BairTL, et al A common variant of the AMPD1 gene predicts improved cardiovascular survival in patients with coronary artery disease. J Am Coll Cardiol. 2000;36(4):1248–52. </plain></SENT>
<SENT sid="414" pm="."><plain>Epub 2000/10/12. .<?supplied-pmid 11028479?>11028479 </plain></SENT>
</text></ref><ref id="pone.0187266.ref025"><text><SENT sid="415" pm="."><plain>25KolekM, CarlquistJ, Thaneemit-ChenS, LazzeroniL, WhitingB, HorneB, et al The Role of a Common Adenosine Monophosphate Deaminase (AMPD)-1 Polymorphism in Outcomes of Ischemic and Nonischemic Heart Failure. Journal of Cardiac Failure. 2005;11(9):677–83. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cardfail.2005.06.437">10.1016/j.cardfail.2005.06.437</ext-link> <?supplied-pmid 16360962?>16360962 </plain></SENT>
</text></ref><ref id="pone.0187266.ref026"><text><SENT sid="416" pm="."><plain>26YazakiY, MuhlesteinJB, CarlquistJF, BairTL, HorneBD, RenlundD, et al A Common Variant of the AMPD1 Gene Predicts Improved Survival in Patients With Ischemic Left Ventricular Dysfunction. Journal of Cardiac Failure. 2004;10(4):316–20. <?supplied-pmid 15309698?>15309698 </plain></SENT>
</text></ref><ref id="pone.0187266.ref027"><text><SENT sid="417" pm="."><plain>27ToyamaK, MorisakiH, KitamuraY, GrossM, TamuraT, NakahoriY, et al Haplotype analysis of human AMPD1 gene: origin of common mutant allele. J Med Genet. 2004 6;41(6):e74 doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/jmg.2003.013151">10.1136/jmg.2003.013151</ext-link> <?supplied-pmid 15173240?>15173240 </plain></SENT>
</text></ref><ref id="pone.0187266.ref028"><text><SENT sid="418" pm="."><plain>28GrossM, RötzerE, KölleP, MortierW, ReichmannH, GoebelHH, et al A G468-T AMPD1 mutant allele contributes to the high incidence of myoadenylate deaminase deficiency in the Caucasian population. Neuromuscul Disord. 2002 8;12(6):558–65. .<?supplied-pmid 12117480?>12117480 </plain></SENT>
</text></ref><ref id="pone.0187266.ref029"><text><SENT sid="419" pm="."><plain>29FischerS, DrenckhahnC, WolfC, EschrichK, KellermannS, FrosterUG, et al Clinical significance and neuropathology of primary MADD in C34-T and G468-T mutations of the AMPD1 gene. Clin Neuropathol. 2005 Mar-Apr;24(2):77–85. .<?supplied-pmid 15803807?>15803807 </plain></SENT>
</text></ref><ref id="pone.0187266.ref030"><text><SENT sid="420" pm="."><plain>30TanakaH, MonahanK, SealsDR. Age-Predicted Maximal Heart Rate Revisited. J Am Coll Cardiol. 2001;37(1):153–6. <?supplied-pmid 11153730?>11153730 </plain></SENT>
</text></ref><ref id="pone.0187266.ref031"><text><SENT sid="421" pm="."><plain>31CamardaSR, TebexreniAS, PáfaroCN, SasaiFB, TambeiroVL, JulianoY, et al Comparison of maximal heart rate using the prediction equations proposed by Karvonen and Tanaka. Arq Bras Cardiol. 2008;11; 91(5):311–4. <?supplied-pmid 19142375?>19142375 </plain></SENT>
</text></ref><ref id="pone.0187266.ref032"><text><SENT sid="422" pm="."><plain>32FengAF, LiuZH, ZhouSL, ZhaoSY, ZhuYX, WangHX. Effects of AMPD1 gene C34T polymorphism on cardiac index, blood pressure and prognosis in patients with cardiovascular diseases: a meta-analysis. Bmc Cardiovascular Disorders. 2017;17 Artn 174 doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12872-017-0608-0">10.1186/s12872-017-0608-0</ext-link> <?supplied-pmid 28673246?>28673246 </plain></SENT>
</text></ref><ref id="pone.0187266.ref033"><text><SENT sid="423" pm="."><plain>33ValenPA, NakayamaDA, VeumJ, SulaimanAR, WortmannRL. Myoadenylate deaminase deficiency and forearm ischemic exercise testing. Arthritis Rheum. 1987;30(6):661–8. </plain></SENT>
<SENT sid="424" pm="."><plain>Epub 1987/06/01. .<?supplied-pmid 3606685?>3606685 </plain></SENT>
</text></ref><ref id="pone.0187266.ref034"><text><SENT sid="425" pm="."><plain>34GrealyR, HerruerJ, SmithCLE, HillerD, HaselerLJ, GriffithsLR. Evaluation of a 7-Gene Genetic Profile for Athletic Endurance Phenotype in Ironman Championship Triathletes. PLoS One. 2015;10(12):e0145171 doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0145171">10.1371/journal.pone.0145171</ext-link> <?supplied-pmid 26716680?>26716680 </plain></SENT>
</text></ref><ref id="pone.0187266.ref035"><text><SENT sid="426" pm="."><plain>35HanischF, JoshiP, ZierzS. AMP deaminase deficiency in skeletal muscle is unlikely to be of clinical relevance. J Neurol. 2008;255(3):318–22. </plain></SENT>
<SENT sid="427" pm="."><plain>Epub 2008/03/14. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00415-008-0530-6">10.1007/s00415-008-0530-6</ext-link> .<?supplied-pmid 18338202?>18338202 </plain></SENT>
</text></ref><ref id="pone.0187266.ref036"><text><SENT sid="428" pm="."><plain>36FishbeinWN, ArmbrustmacherVW, GriffinJL, DavisJI, FosterWD. Levels of adenylate deaminase, adenylate kinase, and creatine kinase in frozen human muscle biopsy specimens relative to type 1/type 2 fiber distribution: evidence for a carrier state of myoadenylate deaminase deficiency. Ann Neurol. 1984;15(3):271–7. </plain></SENT>
<SENT sid="429" pm="."><plain>Epub 1984/03/01. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/ana.410150312">10.1002/ana.410150312</ext-link> .<?supplied-pmid 6326659?>6326659 </plain></SENT>
</text></ref><ref id="pone.0187266.ref037"><text><SENT sid="430" pm="."><plain>37FishbeinWN. Primary, secondary, and coincidental types of myoadenylate deaminase deficiency. Ann Neurol. 1999;45(4):547–8. </plain></SENT>
<SENT sid="431" pm="."><plain>Epub 1999/04/22. .<?supplied-pmid 10211487?>10211487 </plain></SENT>
</text></ref><ref id="pone.0187266.ref038"><text><SENT sid="432" pm="."><plain>38MöserG, SchraderJ, DeussenA. Turnover of adenosine in plasma of human and dog blood. Am J Physiol. 1989;4; 256(4 Pt 1):C799–806. <?supplied-pmid 2539728?>2539728 </plain></SENT>
</text></ref><ref id="pone.0187266.ref039"><text><SENT sid="433" pm="."><plain>39LeeH, ThompsonCI, HernandezA, LewyJL, BelloniFL. Cardiac desensitization to adenosine analogues after prolonged R-PIA infusion in-vivo. Am J Physiol. 1993;Dec;265(6 Pt 2):H1916–27. <?supplied-pmid 8285230?>8285230 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
